Journal: bioRxiv

Article Title: Tissue-wide profiling of human lungs reveals spatial sequestration of macrophages in tuberculosis

doi: 10.1101/2025.04.11.648467

Figure Lengend Snippet: (A) Heatmap showing the relative abundance of CD4 + (top) and CD8 + (bottom) T cell sub-populations in each lesion type. Rows are ordered based on the similarity in marker expression patterns. N, the border of necrotic lesions. (B) Representative OPAL multi-plex image illustrating a germinal center-like structure in a B3-type lesion. The image with merged DAPI, CD20, BCL6, and PNAd is shown. Arrows indicate PNAd + high endothelial venules and arrow heads indicate BCL6 + B cells. (C) Paired analysis comparing the spatial association relationships between B cells and Tfh (C10) or proinflammatory CD4 + T cells (C08) in all B3-type lesions. Each line indicates a lesion. The level of statistical significance is determined using Wilcoxon signed-rank test, **** P < 0.0001. (D) Cell type pheno-map of a representative B3-type lesion with cell type indicated. (E) Scatter plots showing the spatial centrality index (immCPI) of Tfh (C10), proinflammatory CD4 + T cells (C08), and proinflammatory CD8 + T cells (C11) in all B3-type lesions ( n = 110). The level of statistical significance is determined using a Mann-Whitney U test, **** P < 0.0001. (F) Heatmap showing the median value of pair-wised spatial association relationships between CD4 + and CD8 + T cell subsets in B3 (left) and T (right) type lesions. (G) Column scatter plot showing spatial relationship between macrophages and CD4 + and CD8 + T cell subtypes in T-type lesions. (H) Heatmap indicating statistical significance from post hoc multi-group comparison results in (G) using a One-way ANOVA test, the level of significance was set at P = 0.05.

Article Snippet: Next, tissue sections were incubated for 1 hour at room temperature with primary antibodies against CD20 (1:100, L26, Abcam), CD4 (1:100, EPR6855, Abcam), and overnight under 4°C with BCL6 (1:100, EPR11410-43, Abcam), and PNAd (1:200, MECA-79, Novus Biologicals).

Techniques: Marker, Expressing, MANN-WHITNEY, Comparison

Journal: Scientific Reports

Article Title: Anti-IL-6 eluting immunomodulatory biomaterials prolong skin allograft survival

doi: 10.1038/s41598-019-42349-w

Figure Lengend Snippet: Local release of anti-IL-6 from IMB suppresses LN fibrosis. The skin allografts were harvested at 7 days post-transplantation. ( A-i ) Lymphatic vessel expansion (Lyve-1 + ) and HEV elongation (MECA79 + ) were similar between all groups. ( A-ii,iii ) Dense staining of collagen I and PDPN was seen in DLNs harvested from control and GelMA group compared to those from GelMA/anti-IL-6 group. (representative images from 4 different mice per group).

Article Snippet: Samples were cut into 5 μm-thick sections and stained with Lyve-1 (Abcam, #ab14917; 1:300), CD11b (Abcam, #ab8878; 1:250), CD11c (Biolegend, #101206; 1:100), CD169 (Biolegend, #142406; 1:100), CD3 (Abcam, #ab16669; 1:250), MECA79 (Novus Biologicals, #NB100-77673; 1:200), Collagen I (Novus Biologicals, #NB600-408; 1:200), and PDPN (R&D System, #AF3244; 1:200) antibodies.

Techniques: Transplantation Assay, Staining, Control

Journal: Journal of Nuclear Medicine

Article Title: Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

doi: 10.2967/jnumed.118.214684

Figure Lengend Snippet: NCI SBIR–Funded TRT Contracts for 2015

Article Snippet: 2016 , Rockland Immunochemicals, Inc. , Phase I , HER2-positive cancers , 68 Ga and 177 Lu , HER2 and digoxigenin , Phase I: Develop bispecific recombinant single-domain antibodies with one arm targeting cancer biomarker HER2 and another arm against digoxigenin; investigate in vivo clearance, tumor accumulation, stability, and ability to capture digoxigenylated fluorescence dyes and radionuclides.

Techniques: In Vitro, In Vivo, Marker, Fluorescence, Drug discovery, Imaging

Journal: Journal of Nuclear Medicine

Article Title: Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

doi: 10.2967/jnumed.118.214684

Figure Lengend Snippet: NCI SBIR–Funded TRT Contracts from 2016 to 2017

Article Snippet: 2016 , Rockland Immunochemicals, Inc. , Phase I , HER2-positive cancers , 68 Ga and 177 Lu , HER2 and digoxigenin , Phase I: Develop bispecific recombinant single-domain antibodies with one arm targeting cancer biomarker HER2 and another arm against digoxigenin; investigate in vivo clearance, tumor accumulation, stability, and ability to capture digoxigenylated fluorescence dyes and radionuclides.

Techniques: Radioactivity, Drug discovery, Recombinant, Biomarker Discovery, In Vivo, Fluorescence, Binding Assay, Labeling, In Vitro, Produced, Software